Protagenic Financial Statements From 2010 to 2024

PTIX Stock  USD 0.73  0.08  12.31%   
Protagenic Therapeutics financial statements provide useful quarterly and yearly information to potential Protagenic Therapeutics investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Protagenic Therapeutics financial statements helps investors assess Protagenic Therapeutics' valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Protagenic Therapeutics' valuation are summarized below:
Market Capitalization
M
Earnings Share
(1.27)
We have found one hundred twenty available trending fundamental ratios for Protagenic Therapeutics, which can be analyzed and compared to other ratios and to its competitors. All investors should make sure to check out all of Protagenic Therapeutics recent market performance against the performance between 2010 and 2024 to make sure the company can sustain itself down the road. Market Cap is likely to drop to about 4.7 M in 2024. Enterprise Value is likely to drop to about 3.3 M in 2024
Check Protagenic Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Protagenic Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 26.8 K, Interest Expense of 87.3 K or Selling General Administrative of 1.1 M, as well as many indicators such as Price To Sales Ratio of 0.28, Dividend Yield of 0.0 or PTB Ratio of 1.11. Protagenic financial statements analysis is a perfect complement when working with Protagenic Therapeutics Valuation or Volatility modules.
  
Check out the analysis of Protagenic Therapeutics Correlation against competitors.
For more information on how to buy Protagenic Stock please use our How to Invest in Protagenic Therapeutics guide.

Protagenic Therapeutics Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total Assets4.1 M4.3 M2.4 M
Slightly volatile
Short and Long Term Debt Total294.3 K309.8 K790.1 K
Slightly volatile
Other Current Liabilities514.4 K541.5 K505 K
Pretty Stable
Total Current Liabilities622.5 K655.3 K1.7 M
Pretty Stable
CashM1.3 M695.9 K
Slightly volatile
Cash And Short Term InvestmentsM4.1 M2.4 M
Slightly volatile
Common Stock Shares Outstanding4.6 M4.3 M2.2 M
Slightly volatile
Liabilities And Stockholders Equity4.1 M4.3 M3.2 M
Pretty Stable
Other Current Assets136.8 K144 K134.3 K
Slightly volatile
Other Stockholder Equity42.6 M34.6 M38.6 M
Slightly volatile
Total Liabilities622.5 K655.3 KM
Pretty Stable
Total Current Assets7.2 M4.2 M2.6 M
Slightly volatile
Common Stock422444134.5 K
Slightly volatile
Accounts Payable108.1 K113.8 K1.2 M
Slightly volatile
Capital Stock759444978
Slightly volatile

Protagenic Therapeutics Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization26.8 K28.2 K77.5 K
Slightly volatile
Selling General Administrative1.1 M1.2 M1.3 M
Slightly volatile
Other Operating Expenses4.3 M4.5 M2.6 M
Slightly volatile
Selling And Marketing Expenses24.1 K25.4 K1.7 M
Slightly volatile
Research Development3.5 M3.3 M972.3 K
Slightly volatile
Interest Income318.4 K303.2 K57.8 K
Slightly volatile
Reconciled Depreciation1.7 K1.6 K371
Slightly volatile

Protagenic Therapeutics Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Begin Period Cash Flow204.4 K215.2 K601.9 K
Very volatile
Depreciation26.8 K28.2 K32.5 K
Slightly volatile
End Period Cash Flow1.9 M1.3 M690.9 K
Slightly volatile
Stock Based Compensation871.1 K666.8 K651.5 K
Slightly volatile
Net Borrowings1.6 M1.5 M748.2 K
Slightly volatile

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio0.280.3277
Slightly volatile
Days Sales Outstanding94.5856.9555.6472
Very volatile
Average Payables205.3 K195.5 K78.4 K
Slightly volatile
Stock Based Compensation To Revenue0.02630.0250.0234
Slightly volatile
Capex To Depreciation5.045.3078739
Slightly volatile
EV To Sales0.110.12281
Slightly volatile
Inventory Turnover1.191.41.5038
Pretty Stable
Days Of Inventory On Hand275270243
Pretty Stable
Payables Turnover0.240.2480.2473
Slightly volatile
Sales General And Administrative To Revenue0.190.21.9608
Slightly volatile
Research And Ddevelopement To Revenue0.00320.00360.0039
Slightly volatile
Capex To Revenue0.00110.00120.0138
Slightly volatile
Cash Per Share0.890.933690.7651
Slightly volatile
Days Payables Outstanding1.4 K1.5 K282.4 K
Slightly volatile
Income Quality0.950.74070.5455
Slightly volatile
Intangibles To Total Assets0.190.180.1728
Slightly volatile
Current Ratio6.736.40983.4636
Slightly volatile
Receivables Turnover3.616.636.8524
Very volatile
Graham Number4.444.6762.5 K
Slightly volatile
Capex Per Share0.03280.03450.0562
Slightly volatile
Revenue Per Share376.4 K353.2 K310.3 K
Slightly volatile
Interest Debt Per Share0.120.13324
Slightly volatile
Debt To Assets0.03660.03851.0781
Slightly volatile
Days Of Payables Outstanding1.4 K1.5 K282.4 K
Slightly volatile
Ebt Per Ebit0.761.10461.0303
Slightly volatile
Quick Ratio6.736.40983.4636
Slightly volatile
Net Income Per E B T0.760.911.0579
Slightly volatile
Cash Ratio2.061.96551.1942
Pretty Stable
Days Of Inventory Outstanding275270243
Pretty Stable
Days Of Sales Outstanding94.5856.9555.6472
Very volatile
Free Cash Flow Operating Cash Flow Ratio1.361.04041.0277
Slightly volatile
Fixed Asset Turnover12.7113.3844.7 K
Slightly volatile
Debt Ratio0.03660.03851.0781
Slightly volatile
Price Sales Ratio0.280.3277
Slightly volatile
Asset Turnover0.951.861.5847
Slightly volatile
Operating Cycle54.1156.9571.9864
Slightly volatile
Cash Conversion Cycle12.3713.0235.7117
Slightly volatile

Protagenic Therapeutics Valuation Data

Current ValueLast YearHistorical Average 10 Year Trend
Market Cap4.7 M4.9 M4.1 M
Slightly volatile
Enterprise Value3.3 M3.5 M3.8 M
Slightly volatile

Protagenic Fundamental Market Drivers

Cash And Short Term Investments4.1 M

Protagenic Upcoming Events

13th of February 2024
Upcoming Quarterly Report
View
31st of December 2023
Next Fiscal Quarter End
View

About Protagenic Therapeutics Financial Statements

Protagenic Therapeutics investors use historical fundamental indicators, such as Protagenic Therapeutics' revenue or net income, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Protagenic Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue(359.19)(341.23)
Cost Of Revenue28.2 K26.8 K
Stock Based Compensation To Revenue 0.03  0.03 
Sales General And Administrative To Revenue 0.20  0.19 
Revenue Per Share353.2 K376.4 K
Ebit Per Revenue(0.64)(0.67)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Protagenic Stock Analysis

When running Protagenic Therapeutics' price analysis, check to measure Protagenic Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Protagenic Therapeutics is operating at the current time. Most of Protagenic Therapeutics' value examination focuses on studying past and present price action to predict the probability of Protagenic Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Protagenic Therapeutics' price. Additionally, you may evaluate how the addition of Protagenic Therapeutics to your portfolios can decrease your overall portfolio volatility.